Stock market today: Stocks fall as investors rotate out of tech into Jackson Hole
SALT LAKE CITY—Lindgardt Zhenya, the Chief Executive Officer of Sera Prognostics , Inc. (NASDAQ:SERA), a $140 million market cap company trading near its 52-week low of $3.84, recently executed a series of transactions involving the company’s Class A common stock, according to a regulatory filing. According to InvestingPro data, the company maintains a strong balance sheet with more cash than debt.
On March 7, Zhenya sold 29,722 shares at a weighted average price of $4.12 per share, totaling approximately $122,454. This transaction was part of a mandated sale to cover tax withholding obligations related to the vesting of restricted stock units (RSUs).
Earlier, on March 6, Zhenya acquired 126,920 shares through the vesting of RSUs at no cost. On the same day, he also acquired stock options for 181,380 shares, exercisable at $4.15 per share, which will vest over four years.
Following these transactions, Zhenya directly owns 876,657 shares of Sera Prognostics.
In other recent news, Sera Prognostics has made several notable announcements. The company has halted its "at-the-market" offering, which had aimed to sell up to $50 million of its Class A common stock. No shares were sold under this arrangement, and the company has not disclosed specific reasons for the termination. In a separate development, Sera Prognostics has launched a public offering of its Class A common stock and pre-funded warrants. The offering includes an option for underwriters to purchase up to 15% more shares, with proceeds intended to expand U.S. and EU operations and support FDA approval efforts for its PreTRM test.
The offering is managed by Jefferies, TD Cowen, William Blair, and RBC Capital Markets and is contingent on market conditions. Additionally, Sera Prognostics revealed that the Society for Maternal Fetal Medicine has published an abstract with topline results from the PRIME study, focusing on neonatal outcomes. A detailed presentation of the study’s findings is scheduled for January 31, 2025, with a follow-up conference call and webcast planned for February 6, 2025. These recent developments highlight Sera Prognostics’ ongoing efforts in research and capital-raising activities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.